Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27.832
Filtrar
1.
BMC Bioinformatics ; 22(1): 178, 2021 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-33823788

RESUMEN

BACKGROUND: The hallmarks of cancer provide a highly cited and well-used conceptual framework for describing the processes involved in cancer cell development and tumourigenesis. However, methods for translating these high-level concepts into data-level associations between hallmarks and genes (for high throughput analysis), vary widely between studies. The examination of different strategies to associate and map cancer hallmarks reveals significant differences, but also consensus. RESULTS: Here we present the results of a comparative analysis of cancer hallmark mapping strategies, based on Gene Ontology and biological pathway annotation, from different studies. By analysing the semantic similarity between annotations, and the resulting gene set overlap, we identify emerging consensus knowledge. In addition, we analyse the differences between hallmark and gene set associations using Weighted Gene Co-expression Network Analysis and enrichment analysis. CONCLUSIONS: Reaching a community-wide consensus on how to identify cancer hallmark activity from research data would enable more systematic data integration and comparison between studies. These results highlight the current state of the consensus and offer a starting point for further convergence. In addition, we show how a lack of consensus can lead to large differences in the biological interpretation of downstream analyses and discuss the challenges of annotating changing and accumulating biological data, using intermediate knowledge resources that are also changing over time.


Asunto(s)
Ontología de Genes , Neoplasias , Semántica , Consenso , Humanos , Anotación de Secuencia Molecular , Neoplasias/diagnóstico , Neoplasias/genética
3.
Mayo Clin Proc ; 96(3): 592-600, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33673912

RESUMEN

OBJECTIVE: To describe the temporal association and identify risk factors between cancer diagnosis and various types of arterial thromboembolism (ATE). PATIENTS AND METHODS: We inquired an aggregated electronic health record database (Explorys, IBM Corp., Armonk, New York) and identified patients with cancer from January 1999 to October 2019, with various types of ATE, including myocardial infarction, acute ischemic stroke, acute limb ischemia, acute mesenteric ischemia, acute renal infarction, and retinal artery occlusion. We investigated the temporal relationship between cancer diagnosis and ATE events by examining the incidence ratio (IR) of ATE before and after diagnosis of cancer. RESULTS: We identified 305,384 patients with cancer and ATE. The 30-day interval IR of total ATE was elevated shortly before and after cancer diagnosis, which was consistent among different ATE and cancer types. The incidence was highest within a 330-day window (90 days before and 240 days after cancer diagnosis), and IR peaked at 13.9 (95% confidence interval [CI], 13.6 to 14.2) in the first 30 days following diagnosis of cancer. Compared with patients with cancer who never developed ATE, patients with ATE had more cardiovascular risk factors at baseline. Patients with brain cancer, lung cancer, colorectal cancer, and pancreatic cancer had the highest risk of developing ATE, whereas ATE type was anatomically associated with cancer type. CONCLUSION: In this observational study of an aggregated US patient population, those with newly diagnosed cancer had increased risk of ATE events. This risk was most elevated in a 330-day window around cancer diagnosis and was consistent across different types of ATE and cancer.


Asunto(s)
Registros Electrónicos de Salud/estadística & datos numéricos , Neoplasias/diagnóstico , Neoplasias/epidemiología , Tromboembolia/diagnóstico , Tromboembolia/epidemiología , Adulto , Anciano , Comorbilidad , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Sistema de Registros , Medición de Riesgo , Factores de Riesgo , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/epidemiología
4.
Eur J Cancer ; 147: 120-127, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33647547

RESUMEN

INTRODUCTION: Coronavirus disease 2019 (COVID-19) pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network (Rete Oncologica Veneta) licenced dedicated guidelines to ensure proper care minimising the risk of infection in patients with cancer. Rete Oncologica Veneta covID19 (ROVID) is a regional registry aimed at describing epidemiology and clinical course of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer. MATERIALS AND METHODS: Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments, as well as details on SARS-CoV-2 infection (hospitalisation, treatments, fate of the infection), have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause. RESULTS: One hundred seventy patients have been enrolled. The median age at time of the SARS-CoV infection was 70 years (25-92). The most common cancer type was breast cancer (n = 40). The majority of the patients had stage IV disease. Half of the patients had two or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%), the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were the following: Eastern Cooperative Oncology Group performance status (PS), age, presence of two or more comorbidities, presence of dyspnoea, COVID-19 phenotype ≥ 3, hospitalisation, intensive care unit admission, neutrophil/lymphocyte ratio and thrombocytopenia. CONCLUSIONS: The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect patients with cancer from SARS-CoV-2 infection.


Asunto(s)
/diagnóstico , Neoplasias/diagnóstico , Neoplasias/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , /patología , Redes Comunitarias , Progresión de la Enfermedad , Femenino , Mortalidad Hospitalaria , Hospitalización/estadística & datos numéricos , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Neoplasias/patología , Pandemias , Pronóstico , Sistema de Registros , Índice de Severidad de la Enfermedad
5.
Eur J Cancer ; 147: 154-160, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33676266

RESUMEN

The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have continued and new relevant data has come to light, maybe most importantly in the field of vaccination studies. Therefore, an update of our guideline on several clinically important topics is warranted. Here, we provide a concise update of evidence-based recommendations for rapid diagnostics, viral shedding, vaccination and therapy of COVID-19 in patients with cancer. This guideline update was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology by critically reviewing the currently available data on these topics applying evidence-based medicine criteria.


Asunto(s)
/normas , Neoplasias , Esparcimiento de Virus/fisiología , Antivirales/uso terapéutico , /epidemiología , /virología , Medicina Basada en la Evidencia/normas , Medicina Basada en la Evidencia/estadística & datos numéricos , Alemania/epidemiología , Neoplasias Hematológicas/diagnóstico , Neoplasias Hematológicas/epidemiología , Neoplasias Hematológicas/terapia , Neoplasias Hematológicas/virología , Hematología/organización & administración , Hematología/normas , Humanos , Inmunización Pasiva/métodos , Inmunización Pasiva/normas , Infectología/organización & administración , Infectología/normas , Oncología Médica/organización & administración , Oncología Médica/normas , Neoplasias/diagnóstico , Neoplasias/epidemiología , Neoplasias/terapia , Neoplasias/virología , Sociedades Médicas/normas , Vacunación/métodos , Vacunación/normas
7.
Bull Cancer ; 108(3): 242-249, 2021 Mar.
Artículo en Francés | MEDLINE | ID: mdl-33648719

RESUMEN

INTRODUCTION: To promote the early diagnosis of pediatric cancers in Ivory Coast, we have initiated a program to train local physicians in the warning signs and to raise public awareness. The aim of this work was to compare the times, stages and survival of patients before and three years after the initiation of the program. METHODS: This retrospective study involved children 0-17 years of age admitted from January to December 2014 and from May 2018 to April 2019. The Mann-Whitney non-parametric test and the Fisher's exact test were used to compare time limits, stages and survival. RESULTS: One hundred and fifty-nine doctors were trained and 1020 people were sensitized. The median age of the 216 children included was 7 years, sex ratio 1.4. For both periods, the median consultation times were 75 and 30 days (P=0.003) and the median diagnostic times were 120 and 105 days (P=0.033). High-risk lymphomas accounted for 60.5% and 58.5% (P=0.99) respectively and nephroblastoma 46.1% and 56.2% (P=0.51). The overall survival was 31% and 30.2% (P=0.92). DISCUSSION: The early diagnosis program had no impact. The diagnosis times and the proportion of cancer classified as high risk are comparable to the data reported in sub-Saharan Africa, which vary respectively from 7 to 15.8 weeks and from 60 to 71%. This program must be intensified, extended to all health workers and include improving access to care.


Asunto(s)
Detección Precoz del Cáncer , Educación Médica , Neoplasias/diagnóstico , Desarrollo de Programa , Evaluación de Síntomas/métodos , Adolescente , Niño , Preescolar , Costa de Marfil , Diagnóstico Tardío , Femenino , Humanos , Lactante , Recién Nacido , Neoplasias Renales/diagnóstico , Neoplasias Renales/mortalidad , Linfoma/diagnóstico , Linfoma/mortalidad , Masculino , Neoplasias/mortalidad , Neoplasias/patología , Médicos , Estudios Retrospectivos , Estadísticas no Paramétricas , Factores de Tiempo , Tumor de Wilms/diagnóstico , Tumor de Wilms/mortalidad
8.
Methods Mol Biol ; 2292: 3-15, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33651347

RESUMEN

Recent reports suggest that urine is a useful noninvasive tool for the identification of urogenital tumors, including bladder, prostate, kidney, and other nonurological cancers. As a liquid biopsy, urine represents an important source for the improvement of new promising biomarkers, a suitable tool to identify indolent cancer and avoid overtreatment. Urine is enriched with DNAs, RNAs, proteins, circulating tumor cells, exosomes, and other small molecules which can be detected with several diagnostic methodologies.We provide an overview of the ongoing state of urinary biomarkers underlying both their potential utilities to improve cancer prognosis, diagnosis, and therapeutic strategy and their limitations.


Asunto(s)
Biomarcadores de Tumor/orina , Neoplasias/orina , Animales , Ácidos Nucleicos Libres de Células/orina , Exosomas/patología , Humanos , Biopsia Líquida/métodos , Neoplasias/diagnóstico , Neoplasias/patología , Ácidos Nucleicos/orina , Proteínas , Proteinuria/diagnóstico , Proteinuria/patología , Proteinuria/orina , Urinálisis/métodos
9.
Methods Mol Biol ; 2292: 57-72, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33651352

RESUMEN

Liquid biopsy is gaining importance in the context of analysis of circulating subcellular components, such as exosomes and nucleic acids, and the investigation of biological fluids is increasing because they express features common to the tissue of origin. Particularly, urine has become one of the most attractive biofluids in clinical practice due to its easy collection approach, its availability of large quantities, and its noninvasiveness. Furthermore, a peculiarity is that, compared to serum or plasma, urine is characterized by a simpler composition that improves isolation and identification of biomarkers. Recent studies have been associated with the investigation of mRNAs and microRNAs as potential noninvasive cancer biomarkers in urine, and to date, several approaches for isolating and measuring urinary nucleic acids have been established, despite still developing. This chapter aims at giving some main published evidences on urinary microRNAs and mRNAs, with the intent to consider their potential translational use in clinical practice.


Asunto(s)
MicroARNs/orina , Neoplasias/orina , ARN Mensajero/orina , Biomarcadores de Tumor/orina , Humanos , Biopsia Líquida , Neoplasias/diagnóstico , Urinálisis
10.
Methods Mol Biol ; 2292: 203-212, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33651364

RESUMEN

The pathogenesis of cancer involves multiple molecular alterations at the level of genome, epigenome, and stromal environment, resulting in several deregulated signal transduction pathways. Metabolites are not only end products of gene and protein expression but also a consequence of the mutual relationship between the genome and the internal environment. Considering that metabolites serve as a comprehensive chemical fingerprint of cell metabolism, metabolomics is emerging as the method able to discover metabolite biomarkers that can be developed for early cancer detection, prognosis, and response to treatment. Urine represents a noninvasive source, available and rich in metabolites, useful for cancer diagnosis, prognosis, and treatment monitoring. In this chapter, we reported the main published evidences on urinary metabolic biomarkers in the studied cancers related to hepatopancreatic and urinary tract with the aim at discussing their promising role in clinical practice.


Asunto(s)
Redes y Vías Metabólicas , Neoplasias/metabolismo , Neoplasias/orina , Animales , Biomarcadores de Tumor/metabolismo , Biomarcadores de Tumor/orina , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/orina , Metaboloma , Metabolómica/métodos , Neoplasias/diagnóstico , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/orina , Pronóstico , Neoplasias Urológicas/diagnóstico , Neoplasias Urológicas/metabolismo , Neoplasias Urológicas/orina
11.
Hautarzt ; 72(4): 307-313, 2021 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-33730256

RESUMEN

In contrast to the obligatory paraneoplasias, which are usually rare, diseases such as Sweet's syndrome, thrombophlebitis or herpes zoster are more common. But they are less frequently associated with neoplasia. The risk of overlooking an associated neoplasm is therefore greater. In this article, prototypic diseases are presented with their clinical appearance, possible pathogenesis and treatment options; this is accompanied by raising awareness of potential associations with cancer. The emphasis on the distinct features of the neoplasm-associated forms should enable more reliable detection of these variants and hopefully contribute to an earlier diagnosis of associated neoplasms. These peculiarities include the jumping or wandering thrombophlebitis occurring as Trousseau's syndrome, recurrent, severe courses with involvement of the oral mucosa in Sweet's syndrome or the necrotizing, gangrenous clinical course, often with a multisegment distribution pattern of herpes zoster. Studies on the association of facultative cutaneous paraneoplasias with certain tumors are presented. However, no general recommendation for tumor screening in patients with herpes zoster, Sweet's syndrome or thrombophlebitis can be given. In atypical courses, particularly severe manifestations or the absence of other causes, more extensive diagnostic procedures appear appropriate in order not to miss possibly associated neoplasms.


Asunto(s)
Neoplasias , Enfermedades de la Piel , Síndrome de Sweet , Tromboflebitis , Humanos , Neoplasias/diagnóstico , Neoplasias/terapia , Piel
13.
Medicine (Baltimore) ; 100(12): e25218, 2021 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-33761709

RESUMEN

BACKGROUND: The relation between the expression of macrophage-colony stimulating factor-1 receptor (CSF-1R) and prognosis of cancer patients has been evaluated in multiple studies, but the results remain controversial. We, therefore, performed a meta-analysis and systematic review to figure out the role of CSF-1R in the prognosis of patients with cancer. METHODS: Several databases were searched, including Web of Science, PubMed, and EMBASE. All human studies were published as full text. The Newcastle-Ottawa risk of bias scale was applied to evaluate the research. We extracted hazard ratios (HRs) with 95% confidence interval (95% CI) which assessed progression-free survival (PFS) and overall survival (OS) in order to assess the impacts of CSF-1R on the prognosis of cancer patients. RESULTS: A total of 12 citations were identified, with studies including 2260 patients in different cancer types that met the eligibility criteria. It was suggested in a pooled analysis that the over-expression of CSF-1R was significantly related to worse PFS (HR: 1.68; P < .001, 1.25-2.10, 95% CI) and also poorer OS (HR=1.28; P < .001, 1.03-1.54, 95% CI). Analysis in subgroups indicated over-expressed CSF-1R was significantly associated with worse OS in hematological malignancy (HR = 2.29; P < .001, 1.49-3.09, 95% CI; model of fixed-effects; I2 = 0.0%, P < .001). Sensitivity analysis suggested that there was no study influencing the stability of the results. CONCLUSIONS: The overexpression of CSF-1R was significantly predictive of worse prognosis in those who suffer from different kinds of malignancies, particularly in hematological malignancy, which indicates that it might be a potential biomarker of prognosis in cancer survival and a potential molecular target in the treatment of malignant tumors.


Asunto(s)
Neoplasias , Biomarcadores de Tumor/metabolismo , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias/diagnóstico , Neoplasias/metabolismo , Neoplasias/mortalidad , Pronóstico , Receptor de Factor Estimulante de Colonias de Macrófagos/metabolismo , Análisis de Supervivencia
16.
Adv Exp Med Biol ; 1316: 25-39, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33740241

RESUMEN

Lipids have many critical biological functions in cancer. There are characteristic changes of lipid metabolism and metabolites in different physiological and pathological processes. Lipidomics is an emerging discipline of metabolomics for systematic analysis of lipids in organisms, tissues, or cells and the molecules that interact with them. With the development of new analytical techniques, especially the application and development of mass spectrometry techniques, the determination of lipids can be carried out quickly and accurately and has a high throughput. A large number of studies have shown that abnormal lipid metabolism is closely related to the occurrence and development of tumors. The application of lipidomics technology can reveal changes in lipids and relative abnormal metabolic pathways associated with tumors. Moreover, it shows a wide range of application prospects in the identification of tumor lipid biomarkers, early tumor diagnosis, and the discovery of antitumor drug targets. This chapter mainly introduces the application and development direction of lipidomics in the diagnosis and therapy of different tumors.


Asunto(s)
Lipidómica , Neoplasias , Humanos , Metabolismo de los Lípidos , Lípidos , Metabolómica , Neoplasias/diagnóstico , Neoplasias/tratamiento farmacológico
19.
Asian Pac J Cancer Prev ; 22(3): 681-690, 2021 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-33773529

RESUMEN

OBJECTIVE: The COVID-19 pandemic has dramatically affected healthcare services around Asia. The Asian National Cancer Centres Alliance and the Asia-Pacific Organisation for Cancer Prevention collaborated to assess the mid- and long- term impact of COVID-19 to cancer care in Asia. METHODS: The two entities organised a combined symposium and post-meeting interactions among representatives of major cancer centres from seventeen Asian countries to outlining major challenges and countermeasures. RESULTS: Participating stakeholders distilled five big questions. 1) "Will there be an explosion of late-stage cancers after the pandemic?" To address and recover from perceived delayed prevention, screening, treatment and care challenges, collaboration of key stakeholders in the region and alignment in cancer care management, policy intervention and cancer registry initiatives would be of essential value. 2) "Operations and Finance" The pandemic has resulted in significant material and financial casualties. Flagged acute challenges (shortages of supplies, imposition of lockdown) as well as longer-standing reduction of financial revenue, manpower, international collaboration, and training should also be addressed. 3) "Will telemedicine and technological innovations revolutionize cancer care?" Deploying and implementing telemedicine such as teleconsultation and virtual tumour boards were considered invaluable. These innovations could become a new regular practice, leading to expansion of tele-collaboration through collaboration of institutions in the region. 4) "Will virtual conferences continue after the pandemic?" Virtual conferences during the pandemic have opened new doors for knowledge sharing, especially for representatives of low- and middle-income countries in the region, while saving time and costs of travel. 5) "How do we prepare for the next pandemic or international emergency?" Roadmaps for action to improve access to appropriate patient care and research were identified and scrutinised. CONCLUSION: Through addressing these five big questions, focused collaboration among members and with international organisations such as City Cancer Challenge will allow enhanced preparedness for future international emergencies.
.


Asunto(s)
Instituciones Oncológicas/organización & administración , Neoplasias/epidemiología , Telemedicina , Asia/epidemiología , Instituciones Oncológicas/economía , Control de Enfermedades Transmisibles , Congresos como Asunto , Diagnóstico Tardío , Prestación de Atención de Salud , Humanos , Neoplasias/diagnóstico , Neoplasias/patología , Neoplasias/terapia , Comunicación por Videocoferencia
20.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-48043

RESUMEN

Ações para o enfrentamento das doenças estão voltadas para o autoconhecimento do corpo no diagnóstico e tratamento precoce


Asunto(s)
Neoplasias/prevención & control , Neoplasias/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...